Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes

What Was Tested

The paper reports a study of Glucagon and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.

The aim of the study was to investigate the different B-cell responses after a glucagon stimulation test (GST) versus mixed meal tolerance test (MMTT).

Who Took Part

The abstract describes 10 people taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

The design is described as randomized and crossover.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

In the crossover set-up each of the people took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are C-Peptide, Diabetes Mellitus, Type 2, Diagnostic Techniques, Endocrine, Eating, Gastric Inhibitory Polypeptide, Glucagon and Glucagon-Like Peptide 1.

The authors tagged it with the keywords B-cell function, glucagon stimulation test, incretin axis and mixed meal tolerance test.

What This Means in Plain Language

The paper is a randomized and crossover study of Glucagon and GIP (Gastric Inhibitory Polypeptide) in 10 people.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2017 (Diabetes/metabolism research and reviews), a journal based in England.

More context: the Glucagon compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.